- Conditions
- Active Dermatomyositis
- Interventions
- BAF312, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Phoenix, Arizona • Los Angeles, California • Orange, California + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 719
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Mature B-cell Malignancies
- Interventions
- ICP-248, Obinutuzumab (G), Rituximab (R)
- Drug
- Lead sponsor
- InnoCare Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Plantation, Florida • Westbury, New York
- Conditions
- Dilated Cardiomyopathy (DCM)
- Interventions
- RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)
- Genetic
- Lead sponsor
- Rocket Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- San Diego, California • Rochester, Minnesota • Charleston, South Carolina
- Conditions
- Pruritus, Atopic Dermatitis
- Interventions
- Asimadoline, Placebo
- Drug
- Lead sponsor
- Tioga Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 249 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • North Miami Beach, Florida + 17 more
- Conditions
- Psoriasis
- Interventions
- CC10004
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • New York, New York
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Atezolizumab
- Drug
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Behavior, Adolescent, Childhood Obesity, Diabetes Mellitus, Type 2, Pediatric Obesity, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases, Overweight, Overnutrition, Nutrition Disorders, Body Weight, Diabetes Mellitus
- Interventions
- Black Girls for Wellness In-Person
- Behavioral
- Lead sponsor
- Cornell University
- Other
- Eligibility
- 12 Years to 18 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Human Papilloma Virus (HPV), High-risk Human Papillomavirus Infection
- Interventions
- Lopinavir / ritonavir
- Drug
- Lead sponsor
- Daré Bioscience, Inc.
- Industry
- Eligibility
- 22 Years to 50 Years · Female only
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 5 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- PT-523 for Injection
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 4
- States / cities
- Miami, Florida • Chicago, Illinois • Durham, North Carolina + 1 more
- Conditions
- Metastatic Melanoma, Liver Metastases
- Interventions
- Nivolumab and Relatlimab, Melphalan
- Drug · Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Acute Spinal Cord Injury
- Interventions
- Glyburide
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- CC-99282, Obinutuzumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Columbus, Ohio • Portland, Oregon + 1 more
- Conditions
- Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
- Interventions
- INNO-206, Doxorubicin
- Drug
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 15 Years to 80 Years
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Stanford, California • Iowa City, Iowa + 2 more
- Conditions
- Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
- Interventions
- BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine, Paclitaxel, Eribulin, BNT327 Optimized Dose, BNT327 Equivalent Q3W Dose
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 13
- States / cities
- Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more
- Conditions
- Multiple Myeloma
- Interventions
- Alnuctamab, Mezigdomide, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • New Haven, Connecticut • New York, New York
- Conditions
- Obsessive Compulsive Disorder (OCD)
- Interventions
- Therapist assisted mobile intervention
- Behavioral
- Lead sponsor
- New York State Psychiatric Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Interventions
- AZD4512 monotherapy
- Combination Product
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 6
- States / cities
- Duarte, California • Jacksonville, Florida • Chicago, Illinois + 3 more
- Conditions
- Acute Lung Injury, ALI, COVID-19
- Interventions
- RLS-0071 10 mg/kg, RLS-0071 40 mg/kg, Placebo
- Drug
- Lead sponsor
- ReAlta Life Sciences, Inc.
- Industry
- Eligibility
- 18 Years to 69 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Plasmodium Falciparum Infection
- Interventions
- Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Crohns Disease
- Interventions
- TRX103, Cyclophosphamide
- Biological · Drug
- Lead sponsor
- Tr1X, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 13
- States / cities
- Scottsdale, Arizona • Sacramento, California • San Francisco, California + 9 more
- Conditions
- Ankle Fractures
- Interventions
- GameReady, RICE
- Device · Other
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- Not listed
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Advanced Cancer
- Interventions
- Nivolumab, Daratumumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more
- Conditions
- Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma
- Interventions
- ATM Kinase Inhibitor AZD1390, Biospecimen Collection, Magnetic Resonance Imaging, Radiation Therapy, Survey Administration
- Drug · Procedure · Radiation + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 22 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
- Conditions
- Alzheimer's Disease and Related Dementias
- Interventions
- EDITH-HC
- Behavioral
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 19 Years to 90 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey